Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
Even if the FDA grants full approval of the Alzheimer’s treatment Leqembi, the rollout will take years.
){kind=link}
){kind=link}
){kind=link}